|
Market Closed -
NYSE
20:00:02 29/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 90.33 USD | +0.42% |
|
-3.34% | +13.82% |
| 10-28 | US estrogen supply crunch widens as women seek alternatives to scarce patches | RE |
| 10-23 | CVS is trying out pharmacists in chronic health management | RE |
| Market Cap | 115B 103B 94.66B 85.94B 161B 10,953B 164B 1,131B 451B 5,740B 432B 423B 18,142B | P/E 2026 * |
13.1x | P/E 2027 * | 12.4x |
|---|---|---|---|---|---|
| Enterprise Value | 167B 149B 137B 125B 233B 15,894B 238B 1,642B 654B 8,329B 626B 613B 26,325B | EV / Sales 2026 * |
0.4x | EV / Sales 2027 * | 0.38x |
| Free-Float |
71.17% | Yield 2026 * |
2.96% | Yield 2027 * | 3.04% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
Xetra
| CVS | Delayed | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
Boerse Muenchen
| CVS | Real-time | |
|
London S.E.
| 0HRS | Delayed | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
Swiss Exchange
| CVS | Delayed | |
|
CBOE
| Real-time | ||
|
CBOE
| 0HRS | Real-time | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Börse Stuttgart
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +0.42% | ||
| 1 week | -3.34% | ||
| Current month | +5.41% | ||
| 1 month | +2.82% | ||
| 3 months | -17.39% | ||
| 6 months | +11.55% | ||
| Current year | +13.82% |
| 1 week | 89.55 |  | 94.77 |
| 1 month | 84.23 | | 95.26 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 16/10/2024 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 11/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 28/02/2007 |
Anne Finucane
BRD | Director/Board Member | 73 | 19/01/2011 |
| Director/Board Member | 71 | 04/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/05/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 31/05/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 21/05/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.42% | -3.34% | +9.89% | +36.26% | 115B | |
| +3.21% | +4.07% | +2.49% | +112.21% | 100B | |
| +2.73% | +5.47% | +129.99% | +1,039.57% | 61.18B | |
| +0.17% | +1.62% | -6.81% | +89.51% | 29.09B | |
| +2.20% | +13.72% | +41.77% | +85.04% | 29.25B | |
| +2.97% | +5.86% | +41.87% | +98.09% | 27.02B | |
| +0.77% | +0.54% | +32.23% | +409.36% | 21.62B | |
| -0.72% | +2.93% | -17.96% | -1.64% | 20.81B | |
| +0.26% | -1.13% | -5.19% | +31.49% | 16.97B | |
| -3.98% | -25.99% | -24.06% | +46.05% | 13.67B | |
| Average | +0.80% | -0.48% | +20.42% | +194.59% | 43.49B | |
| Weighted average by Cap. | +1.47% | +0.05% | +26.21% | +222.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 374B 344B 312B 585B 39,802B 596B 4,111B 1,639B 20,859B 1,569B 1,535B 65,925B | 430B 384B 354B 321B 601B 40,946B 613B 4,230B 1,686B 21,458B 1,614B 1,580B 67,819B |
| Net income | 8.87B 7.93B 7.3B 6.63B 12.41B 845B 12.64B 87.29B 34.79B 443B 33.31B 32.6B 1,400B | 9.32B 8.33B 7.67B 6.96B 13.03B 887B 13.27B 91.65B 36.53B 465B 34.97B 34.23B 1,470B |
| Net Debt | 51.89B 46.37B 42.69B 38.76B 72.55B 4,940B 73.92B 510B 203B 2,589B 195B 191B 8,183B | 48.85B 43.65B 40.19B 36.49B 68.3B 4,651B 69.58B 480B 191B 2,437B 183B 179B 7,703B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | US$90.33 | +0.42% | 10,165,094 |
| 28/10/26 | US$89.95 | -1.29% | 5,578,371 |
| 27/10/26 | US$91.13 | -1.51% | 4,589,666 |
| 26/10/26 | US$92.53 | -1.01% | 4,257,992 |
| 23/10/26 | US$93.47 | -1.07% | 4,601,858 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
